US FDA: Rapid Antigen Covid-19 Tests Less Sensitive to Detect Omicron Variant


On Tuesday, 28 December 2021, the Food and Drug Administration (FDA) of the United States said that, the Rapid Antigen tests have been less sensitive towards the detection of the detection of the new Omicron corona virus variant, and the US FDA said in a statement that, the Rapid Antigen tests are able to detect the new Omicron covid-19 variant, but the tests might be less sensitive towards the Omicron variant of the corona virus.

The US FDA said that, the early data on the Omicron variant of the corona virus has been suggesting that, the antigen tests for the purpose of detecting the Omicron covi-19 variant but the tests might have been decreased the sensitivity.

The US FDA also said that, the information has been mainly based on the results of the primary study and the future evaluation is going to be continuing in the collaboration with the RADx program of the National Institute of Health (NIH) in the country.

READ  US: Oxitec Announced 2022 Pilot Plans for Mosquito Technology

The observation from the US FDA comes at a time when the fear of the Omicron variant has been gripping the whole world, and in the latest comment on the Omicron variant, WHO (World Health Organization) said that, the risks from this new covid-19 variant has been very high.